p21-activated kinase 1: PAK'ed with potential by Ong, Christy C. et al.
www.impactjournals.com/oncotarget/  Oncotarget, June, Vol.2, No 6
Oncotarget 2011; 2:  491 - 492 www.impactjournals.com/oncotarget 491
p21-activated kinase 1: PAK’ed with potential
Christy C. Ong1,*, Adrian M. Jubb2,*, Wei Zhou1, Peter M. Haverty3, Adrian L. 
Harris2, Marcia Belvin1, Lori S. Friedman1, Hartmut Koeppen4, Klaus P. Hoeflich1,5
1 Department of Translational Oncology, Genentech, Inc., South San Francisco, CA 94080, USA 
2 The Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford OX3 9DS, UK 
3 Department of Bioinformatics, Genentech, Inc., South San Francisco, CA 94080, USA
4 Department of Pathology, Genentech, Inc., South San Francisco, CA 94080, USA
* These authors contributed equally to this work.
Correspondence to: Klaus P. Hoeflich, email: hoeflich@gene.com
Keywords: PAK1, apoptosis, squamous, lung cancer, breast cancer
Received:  May 3, 2011, Accepted: June 2, 2011, Published: June 7, 2011
Copyright: © Ong et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which per-
mits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
AbstrAct:
The p21-activated kinases (PAKs) are central players in growth factor signaling 
networks and morphogenetic processes that control proliferation, cell polarity, 
invasion and actin cytoskeleton organization. This raises the possibility that 
interfering with PAK activity may produce significant anti-tumor activity. In this 
perspective, we summarize recent data concerning the contribution of the PAK family 
member, PAK1, in growth factor signaling and tumorigenesis. We further discuss 
mechanisms by which inhibition of PAK1 can arrest tumor growth and promote cell 
apoptosis, and the types of cancers in which PAK1 inhibition may hold promise.
PAK1 signAling in nsclc
PAK serine/threonine protein kinases are subdivided 
into two groups, PAK1-3 (group I) and PAK4-6 (group 
II), based on sequence similarities and an autoinhibitory 
domain which is present in group I, but not group II PAK 
proteins [1,2]. The group I PAKs share a number of other 
conserved structural characteristics, such as a p21-binding 
domain (PBD), a serine/threonine kinase domain, an 
acidic region and multiple proline-rich regions that serve 
as binding sites for SH3 domain-containing proteins. As 
a major downstream effector of the Rho family small 
GTPases Cdc42 and Rac1, PAK1 plays a fundamental 
role in controlling cell motility by linking a variety of 
extracellular signals to changes in actin cytoskeleton 
organization, cell shape and adhesion dynamics (Figure 
1) [3,4,5]. 
PAK1 is the most well characterized family 
member and is widely expressed in a variety of normal 
tissues  [1].  PAK1  expression  is  significantly  increased 
in ovarian, breast and bladder cancers [6,7,8]. In luminal 
breast cancer, the expression and localization of PAK1 
protein was recently assessed in primary tumors from 
403 premenopausal patients that were randomized to 
two years of adjuvant tamoxifen or no treatment [9]. 
Elevated expression and/or nuclear localization of PAK1 
were associated with resistance to tamoxifen therapy [9], 
possibly occurring as a result of direct phosphorylation 
and ligand-independent transactivation of estrogen 
receptor-α  by  PAK1  [10].  Functional  studies  have 
also implicated PAK1 in cell transformation [11], and 
transgenic overexpression of PAK1 in the mammary 
gland promotes the formation of tumors and preneoplastic 
lesions in animal models, albeit with a long latency [12]. 
These  findings  indicate  that  PAK1  may  contribute  to 
tumorigenesis in some disease contexts [13,14]. 
To determine the possible extent of PAK1 
dysregulation across human cancers, we determined 
PAK1 protein expression and subcellular localization 
via immunohistochemical (IHC) staining of primary 
human tissue microarrays from several tumor indications, 
including breast, lung, and head and neck cancers [15]. 
Nearly two-thirds of squamous NSCLC samples in our 
panel were positive for PAK1 protein expression and 
52% (n=67) of all cases showed staining of moderate or 
strong intensity in the malignant cells. In comparison, 
adjacent normal lung tissue did not express appreciable 
protein levels of PAK1. Nuclear localization of PAK1 
was also evident in a significant proportion of squamous 
NSCLC tumors (25%) and it has been shown that nuclear Oncotarget 2011; 2:  491 - 492 492 www.impactjournals.com/oncotarget
import of PAK1 can play a critical role in vertebrate cell 
biology [16]. Supporting evidence that PAK1 expression 
is elevated in squamous NSCLC was also obtained by 
analyzing PAK1 mRNA expression in a distinct set of 
laser-capture microdissected lung tissues (p < 0.0001). 
We subsequently examined the effect of RNAi-
mediated knockdown of PAK1 in a panel of lung cancer 
cell lines to clarify the contribution of PAK1 towards 
tumor cell growth and survival. Transient knockdown 
of PAK1 and PAK2 together resulted in a 2.5- to 8-fold 
reduction in [3H]-thymidine incorporation of multiple 
squamous NSCLC lines when compared with control cells 
(p<0.0001). In addition, we made use of a doxycycline-
inducible short-hairpin RNA (shRNA) system [17,18] to 
study PAK1 loss-of-function effects. Tightly regulated 
Dox-mediated knockdown of PAK1 was observed in 
NSCLC cells and tumor xenografts. Inhibition of PAK1 
resulted in accumulation of cells in the G1 phase of 
the cell cycle, altered levels of E2F and p27Kip1 (which 
play multifaceted roles in regulation of G0 to S phase 
transitions of the cell cycle), and inhibition of in vivo 
tumor growth [19,20]. Furthermore, PAK1 knockdown 
substantially decreased tumor cell proliferation (imaged 
by immunofluorescence staining of Ki-67 positive nuclei), 
migration and actin dynamics induced by hepatocyte 
growth factor (HGF) treatment (Figure 2). Amplification 
or over-expression of c-MET (the receptor for HGF) is 
a known genetic aberration and therapeutic target in 
squamous NSCLC [21,22] and PAK1 may be a key 
effector for HGF/c-MET signaling in cancer. Together, 
these  findings  demonstrate  that  PAK1  is  important  for 
proliferation of a subset of squamous lung cancers in vitro 
and in vivo, and support the possibility that interfering 
with PAK1 activity could have therapeutic efficacy in this 
indication.
imPlicAtions for treAtment of 
squAmous lung cArcinomA
Primary lung cancer is a heterogeneous disease both 
genetically and histologically. It can be subdivided into 
small cell lung cancer (accounting for approximately 20%) 
[23,24], which has a neuroendocrine phenotype, and non-
small cell lung cancer, which comprises adenocarcinomas, 
squamous carcinomas and more rare subtypes. Squamous 
lung carcinoma is a prevalent subtype, accounting for 
figure 1: PAK1 signaling pathways in mammalian cells. Upstream activators of PAK1 include receptor tyrosine kinases (such as 
Met, HER3 and PDGFR), integrins and G-protein coupled receptors. Well-established effectors regulating cellular motility, proliferation 
and survival are shown. PAK1 acts on a number of regulators of the cytoskeleton, including to increase actin and tubulin polymerization.
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33% of primary lung cancers in non-smokers and 42% in 
smokers [23,24]. Historically, differences in the prognosis 
and sensitivity to chemotherapy of adenocarcinomas 
and squamous carcinomas (following correction for 
stage and other confounding variables) were considered 
insufficient  to  warrant  different  treatment.  First  line 
treatment with one of four combination chemotherapy 
regimens was once the standard of care, irrespective of a 
tumour’s histology or genetic makeup, but despite therapy 
two-year survival is only 11% [25]. However, since that 
time several targeted therapies have been approved for 
NSCLC. Bevacizumab, an antibody to VEGF that targets 
tumour blood vessels, has shown improvements in overall 
and/or progression-free survival when combined with 
cytotoxic chemotherapy [26,27]. However, the use of 
bevacizumab specifically excludes squamous NSCLC due 
to haemoptysis [28]. Erlotinib is a small molecular tyrosine 
kinase inhibitor against epidermal growth factor receptor 
(EGFR) that is approved as monotherapy for maintenance 
treatment following platinum-based chemotherapy or as 
monotherapy following the failure of ≥1 chemotherapy 
regimen [29]. While erlotinib is approved for use in 
unselected patients, there is evidence that erlotinib 
and a related drug, gefitinib, show greater activity and 
efficacy  in  cancers  that  harbour  specific  mutations  in 
EGFR and are wildtype for KRAS, an oncogene that 
transduces growth promoting signals downstream of 
EGFR [30]. EGFR mutations are very frequent in lung 
adenocarcinomas (40%), but are infrequent (0-5%) in 
squamous cell carcinomas of the lung [31,32]. Moreover, 
other mutations affecting genes that impinge on the EGFR/
RAS pathway are relatively infrequent (3% PI3KCA, 6% 
KRAS, 2% BRAF and 10% PTEN) [31]. Thus, squamous 
lung carcinoma represents an unmet medical need with a 
poor prognosis and PAK inhibitors could be tested in this 
indication.
PAK1 signAling And breAst cAncer 
PAK1 genomic copy number and protein expression 
level were also ascertained in 216 and 274 human breast 
carcinoma samples, respectively [15]. PAK1 expression 
figure 2: PAK1 regulates actin cytoskeleton morphology and proliferation of squamous nsclc cells. PAK1 is required 
for hepatocyte growth factor (HGF)-induced actin dynamics and proliferation of squamous NSCLC cells. EBC-1 cells were pretreated with 
Dox for 3 days prior to serum starvation for 16 hours and treatment with 50 ng/mL HGF for 1 hour. Cytoskeleton morphology and cell cycle 
progression were detected by staining with phalloidin and Ki-67, respectively. Inducible-knockdown of PAK1 attenuated cell rounding and 
cortical actin distribution, as quantified by measuring cell diameter by image analysis, and reduced nuclear levels of Ki-67. Induction of 
control LacZ shRNA with Dox had no effect in these assays.
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was absent in normal breast epithelial cells, but genomic 
amplification  was  prevalent  in  luminal  subtype  tumors 
and elevated cytoplasmic protein expression was observed 
across 39% of primary adenocarcinomas. Consistent with 
the evolutionarily conserved role for PAK1 in regulating 
cell motility, high PAK1 expression was associated with 
lymph node invasion and occurred more frequently in nodal 
metastases compared to primary tumors. It is interesting 
that the frequency of dysregulated expression of PAK1 
was more frequent than would be predicted by genomic 
amplification alone and additional regulatory mechanisms 
that may increase PAK1 expression in breast cancer, such 
as via microRNA genes [33], remain to be fully explored. 
Analysis of MDA-MB-175, HCC1500 and MDA-MB-
134IV cell lines with PAK1 genomic copy number gain 
revealed exquisite dependence on PAK1 expression and 
activity for cell survival [15]. The pro-survival function 
of PAK1 in breast cancers might be another contributing 
factor to the association of elevated PAK1 expression 
and  reduced  clinical  benefit  in  patients  treated  with 
tamoxifen [9]. Taken together, our identification of PAK1 
as an “Achilles’ heel” for a subpopulation of breast 
cancer provides evidence of oncogene addiction [34] 
and a rationale for PAK1-directed therapy in this disease 
indication. 
rAtionAl therAPeutic strAtegies 
for combining with PAK1 
inhibition
Despite the exquisite sensitivity of the breast 
cancer cell lines harboring genomic copy gains to PAK1 
knockdown, inhibition of PAK1 did not generally increase 
apoptosis of NSCLC cells and xenograft models. We 
therefore hypothesized that PAK1 inhibition may synergize 
with other molecularly targeted agents to augment 
killing of tumor cells. We also reasoned that testing the 
combination of PAK1 inhibition plus compounds of 
known cellular mechanism would aid in understanding 
the cellular function of PAK1 in NSCLC cells as well as in 
rationally designing effective combination regimens that 
could be readily translated into the clinic. Hence, a cellular 
viability screen was performed using shPAK1 isogenic 
cells and a panel of 200 small molecule compounds that 
included oncology drugs approved by the FDA, signaling 
pathway inhibitors and DNA damaging agents. Among the 
tested compounds, antagonists of inhibitor of apoptosis 
proteins (IAP), epidermal growth factor receptor (EGFR), 
MAPK/ERK kinase-1/2 (MEK1/2) and Src family kinases 
displayed enhanced efficacy in the context of combined 
PAK1 knockdown [15]. A number of antagonists have 
been described to disrupt the association of IAP with the 
second mitochondrial activator of caspases (SMAC) and 
activated caspase-9 [35,36] and this protein family was 
selected for follow-up studies. Consistent with the small 
molecule screening data, strong combinatorial activity 
and induction of programmed cell death were confirmed 
for PAK1 and IAP dual inhibition with EBC-1 and 
additional NSCLC cell lines. Our recent published work 
demonstrates a fundamental role for PAK1 in NSCLC 
biology and provides support for PAK1 as a therapeutic 
target in this tumor indication.
conclusions
In summary, recent work on the PAK family 
of kinases has focused on the role of these proteins 
in cellular functions relevant to tumor initiation and 
maintenance, namely cell proliferation and survival 
signaling [13,37,38,39]. We assessed the role of 
PAK1 in a large panel of human tumors (via high 
resolution, single-nucleotide polymorphism arrays and 
immunohistochemical staining) and in vivo tumor models 
(via inducible RNA interference) and showed that PAK1 
inhibition resulted in improved anti-tumor efficacy [15]. 
It will be of great interest to expand on these efficacy 
experiments by utilizing genetically engineered mouse 
models to continue evaluating the therapeutic benefit of 
PAK1 inhibition [40,41]. PAK1 inhibition also promoted 
tumor cell apoptosis as either single-agent treatment (in 
the context of tumor cells with focal genomic amplification 
of PAK1) or as combination therapy with several targeted 
agents (in squamous cell carcinomas). It will be important 
to more thoroughly characterize PAK1 effector signaling 
and possible molecular mechanisms for regulation of 
cell survival in squamous NSCLC. For instance, PAK1 
signaling in squamous NSCLC cells was associated 
with an accumulation of the anti-apoptotic BCL2 family 
member, myeloid cell leukemia-1 (Mcl-1), and suggests 
a combination with BCL2 inhibitors such as Navitoclax/
ABT-263 [42]. Nuclear factor κB (NF-κB) subunits 
were also differentially phosphorylated following PAK1 
inhibition in multiple squamous NSCLC cell lines and this 
pathway may contribute to transformation of lung cancer 
cells [43,44]. Taken together, we describe evidence for 
dysregulation of PAK1 in breast and squamous NSCLC 
tumors and a role for PAK1 in cellular survival and 
proliferation in these indications.
AcKnowledgements
A. Jubb is supported by a career development 
fellowship from the Pathological Society of Great Britain 
and Ireland. A. Harris is supported by Cancer Research 
UK and the Oxford NHS Biomedical Research Centre. 
We thank Karen Lyle and colleagues at Genentech for 
insightful discussions and technical assistance. 
references
1.  Arias-Romero LE, Chernoff J. A tale of two Paks. Biol 
Cell. 2008; 100: 97-108.Oncotarget 2011; 2:  491 - 496 495 www.impactjournals.com/oncotarget
2.  Eswaran J, Soundararajan M, Knapp S. Targeting group 
II PAKs in cancer and metastasis. Cancer Metastasis Rev. 
2009; 28: 209-17.
3.  Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, 
Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal 
reorganization and cell migration through the p21-activated 
kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem. 
1998; 273: 28238-46.
4.  Delorme V, Machacek M, DerMardirossian C, Anderson 
KL, Wittmann T, Hanein D, Waterman-Storer C, Danuser G, 
Bokoch GM. Cofilin activity downstream of Pak1 regulates 
cell protrusion efficiency by organizing lamellipodium and 
lamella actin networks. Dev Cell. 2007; 13: 646-62.
5.  Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch 
GM, Chernoff J. Human p21-activated kinase (Pak1) 
regulates actin organization in mammalian cells. Curr Biol. 
1997; 7: 202-10.
6.  Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, 
Vadlamudi RK, Kumar R. p21-activated kinase-1 signaling 
mediates cyclin D1 expression in mammary epithelial and 
cancer cells. J Biol Chem. 2004; 279: 1422-8.
7.  Ito M, Nishiyama H, Kawanishi H, Matsui S, Guilford 
P, Reeve A, Ogawa O. P21-activated kinase 1: a new 
molecular marker for intravesical recurrence after 
transurethral resection of bladder cancer. J Urol. 2007; 178: 
1073-9.
8.  Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, 
Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch 
MJ, Moch H. Combined array comparative genomic 
hybridization and tissue microarray analysis suggest PAK1 
at 11q13.5-q14 as a critical oncogene target in ovarian 
carcinoma. Am J Pathol. 2003; 163: 985-92.
9.  Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg 
G. Association between Pak1 expression and subcellular 
localization and tamoxifen resistance in breast cancer 
patients. J Natl Cancer Inst. 2006; 98: 671-80.
10. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, 
Barnes CJ, Wang RA, Aldaz M, Khan S, Kumar R. P21-
activated kinase 1 regulation of estrogen receptor-alpha 
activation involves serine 305 activation linked with serine 
118 phosphorylation. Cancer Res. 2006; 66: 1694-701.
11.  Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen 
D, Sahin A, Chernoff J, Hung MC, Kumar R. Regulatable 
expression of p21-activated kinase-1 promotes anchorage-
independent growth and abnormal organization of mitotic 
spindles in human epithelial breast cancer cells. J Biol 
Chem. 2000; 275: 36238-44.
12.  Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R. 
PAK1  hyperactivation  is  sufficient  for  mammary  gland 
tumor formation. Oncogene. 2006; 25: 2931-6.
13.  Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in 
cancer. Nat Rev Cancer. 2006; 6: 459-71.
14.  Erkan EP, Breakefield XO, Saydam O. miRNA signature 
of schwannomas: possible role(s) of “tumor suppressor” 
miRNAs in benign tumors. Oncotarget. 2011; 2: 265-70.
15.  Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong 
T, Turley H, O’Brien T, Vucic D, Harris AL, Belvin M, 
Friedman  LS,  Blackwood  EM,  Koeppen  H,  Hoeflich 
KP. Targeting p21-activated kinase 1 (PAK1) to induce 
apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2011; 
108: 7177-82.
16. Lightcap CM, Kari G, Arias-Romero LE, Chernoff J, 
Rodeck U, Williams JC. Interaction with LC8 is required 
for Pak1 nuclear import and is indispensable for zebrafish 
development. PLoS One. 2009; 4: e6025.
17.  Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower 
J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis 
DP, Seshagiri S. Oncogenic BRAF is required for tumor 
growth and maintenance in melanoma models. Cancer Res. 
2006; 66: 999-1006.
18.  Gray DC, Hoeflich KP, Peng L, Gu Z, Gogineni A, Murray 
LJ, Eby M, Kljavin N, Seshagiri S, Cole MJ, Davis DP. 
pHUSH: a single vector system for conditional gene 
expression. BMC Biotechnol. 2007; 7: 61.
19.  Hallstrom TC, Nevins JR. Balancing the decision of cell 
proliferation and cell fate. Cell Cycle. 2009; 8: 532-5.
20.  Wander SA, Zhao D, Slingerland JM. p27: a barometer of 
signaling deregulation and potential predictor of response 
to targeted therapies. Clin Cancer Res. 2010; 17: 12-8.
21.  Herbst RS, Heymach JV, Lippman SM. Lung cancer. N 
Engl J Med. 2008; 359: 1367-80.
22.  Spigel D. Randomized multicenter double-blind placebo- 
controlled phase II study evaluating MetMAb, an antibody 
to met receptor, in combination with erlotinib, in patients 
with advanced non-small-cell lung cancer. European 
Society for Medical Oncology (ESMO) Congress. 2010.
23. Bryant A, Cerfolio RJ. Differences in epidemiology, 
histology, and survival between cigarette smokers and 
never-smokers who develop non-small cell lung cancer. 
Chest. 2007; 132: 185-92.
24.  Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 
1995; 75: 191-202.
25.  Schiller JH, Harrington D, Belani CP, Langer C, Sandler 
A, Krook J, Zhu J, Johnson DH. Comparison of four 
chemotherapy regimens for advanced non-small-cell lung 
cancer. N Engl J Med. 2002; 346: 92-8.
26.  Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova 
V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, 
Manegold C. Phase III trial of cisplatin plus gemcitabine 
with either placebo or bevacizumab as first-line therapy for 
nonsquamous non-small-cell lung cancer: AVAil. J Clin 
Oncol. 2009; 27: 1227-34.
27.  Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, 
Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-
carboplatin alone or with bevacizumab for non-small-cell 
lung cancer. N Engl J Med. 2006; 355: 2542-50.
28. Avastin Prescribing Information. [http://wwwgenecom/
gene/products/information/pdf/avastin-prescribingpdf].Oncotarget 2011; 2:  491 - 496 496 www.impactjournals.com/oncotarget
29. Tarceva Prescribing Information. [http://wwwgenecom/
gene/products/information/pdf/tarceva-prescribingpdf].
30.  NCCN Guidelines for Treatment of Cancer by Site.
 [http://www.nccn.org/professionals/physician_gls/f_
guidelines.asp].
31.  Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare 
D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, 
Campbell PJ, Stratton MR, Futreal PA. COSMIC: mining 
complete cancer genomes in the Catalogue of Somatic 
Mutations in Cancer. Nucleic Acids Res. 2010; 39: D945-
50.
32.  Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore 
S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti 
A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in 
non-small-cell lung cancer: analysis of a large series of 
cases and development of a rapid and sensitive method 
for diagnostic screening with potential implications on 
pharmacologic treatment. J Clin Oncol. 2005; 23: 857-65.
33.  Reddy SD, Ohshiro K, Rayala SK, Kumar R. MicroRNA-7, 
a homeobox D10 target, inhibits p21-activated kinase 1 and 
regulates its functions. Cancer Res. 2008; 68: 8195-200.
34.  Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 
2008; 68: 3077-80.
35.  Zobel K, Wang L, Varfolomeev E, Franklin MC, Elliott 
LO, Wallweber HJ, Okawa DC, Flygare JA, Vucic D, 
Fairbrother WJ, Deshayes K. Design, synthesis, and 
biological activity of a potent Smac mimetic that sensitizes 
cancer cells to apoptosis by antagonizing IAPs. ACS Chem 
Biol. 2006; 1: 525-33.
36.  Varfolomeev E, Blankenship JW, Wayson SM, Fedorova 
AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott 
LO, Wallweber HJ, Flygare JA, Fairbrother WJ, 
Deshayes K, Dixit VM, Vucic D. IAP antagonists induce 
autoubiquitination of c-IAPs, NF-kappaB activation, and 
TNFalpha-dependent apoptosis. Cell. 2007; 131: 669-81.
37.  Arias-Romero LE, Villamar-Cruz O, Pacheco A, Kosoff 
R, Huang M, Muthuswamy SK, Chernoff J. A Rac-
Pak signaling pathway is essential for ErbB2-mediated 
transformation of human breast epithelial cancer cells. 
Oncogene. 2010; 29: 5839-49.
38.  Chow HY, Stepanova D, Koch J, Chernoff J. p21-Activated 
kinases are required for transformation in a cell-based 
model of neurofibromatosis type 2. PLoS One. 2010; 5: 
e13791.
39.  Liu Y, Chen N, Cui X, Zheng X, Deng L, Price S, Karantza 
V, Minden A. The protein kinase Pak4 disrupts mammary 
acinar architecture and promotes mammary tumorigenesis. 
Oncogene. 2010; 29: 5883-94.
40.  McDaniel AS, Allen JD, Park SJ, Jaffer ZM, Michels 
EG, Burgin SJ, Chen S, Bessler WK, Hofmann C, Ingram 
DA, Chernoff J, Clapp DW. Pak1 regulates multiple c-Kit 
mediated Ras-MAPK gain-in-function phenotypes in 
Nf1+/- mast cells. Blood. 2008; 112: 4646-54.
41.  Singh M, Johnson L. Using genetically engineered mouse 
models of cancer to aid drug development: an industry 
perspective. Clin Cancer Res. 2006; 12: 5312-28.
42.  Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen 
J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer, P, 
Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, et 
al. ABT-263: a potent and orally bioavailable Bcl-2 family 
inhibitor. Cancer Res. 2008; 68: 3421-8.
43.  Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, 
Ouyang C, Jacks T. Requirement for NF-kappaB signalling 
in a mouse model of lung adenocarcinoma. Nature. 2009; 
462: 104-7.
44.  Frost  JA,  Swantek  JL,  Stippec  S,  Yin  MJ,  Gaynor  R, 
Cobb MH. Stimulation of NFkappa B activity by multiple 
signaling pathways requires PAK1. J Biol Chem. 2000; 
275: 19693-9.